|   Press Release

Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium

Life science-focused venture capital firms Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners (OUP) have partnered to create Science2Startup (S2S)™, an invitation-only symposium aimed at strengthening connections between biotech investors and therapeutics researchers at the world’s top academic research institutions. S2S will take place on April 23, 2019, in Cambridge at the Broad Institute of MIT and Harvard.

Read more.


  |   From the Trenches

Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations

Every morning before I go to work, I review my calendar for the day. This gets me into the right frame of mind and helps me set my priorities. On Thursday, January 3, 2019, I reviewed my schedule and saw that I had a clear calendar: dermatologist appointment, management team meeting, and nothing else.

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Cats And The Future Of Machine Learning In Drug Discovery

The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that not everyone is convinced and the trajectory of the current AI hype cycle feels downwards.

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   Uncategorized

Atlas Venture People News – April 2019

Atlas Venture portfolio companies have been busy recruiting all-star talent to their teams and boards. Check out some of the recent additions on our People News postcard!

View the postcard.


  |   In the News

Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease

One problem with drugs for muscular disorders is that not enough medicine reaches the muscle, says Romesh Subramanian, CEO of Dyne Therapeutics. Subramanian’s startup has developed a way to target delivery of drugs to all muscle types, and it is emerging from stealth with $50 million in funding to advance its compounds toward human testing.

Read more.